The authors assessed the effectiveness of different screening techniques for colorectal cancer (CRC) in asymptomatic people at normal or an above average risk.
Sigmoidoscopy was assessed in three randomised trials (FOBT versus sigmoidoscopy alone or combined with FOBT, n=15,610), two diagnostic cohorts and three case control studies, including one retrospective analysis of patient charts from a randomised trial.
Uniphase screening with colonoscopy was assessed in four uncontrolled trials and by reanalysis of data from one casecontrol study and one randomised trial.
Data from retrospective diagnostic case-control studies and cohort studies were used to assess screening strategies for people with a family history of polyps or colon cancer, and those at risk of familial adenomatous polyps and hereditary nonpolyposis colon cancer.
The most rigorous evidence was available for Hemoccult testing. Four randomised trials found the sensitivity of an annual screen ranged from 48 to 79%, with the relative risk of death from CRC ranging from 0.67 to 0.88. Other findings were presented in the review.
Authors' conclusions
There was some evidence to support annual or biennial FOBT and flexible sigmoidoscopy in asymptomatic people aged over 50 years who were at normal risk of CRC. The relative benefits of FOBT and sigmoidoscopy are uncertain in this population. Evidence for the use of colonoscopy as an initial screen was also unclear.
For people with an above average risk of CRC there was some evidence for genetic testing, flexible sigmoidoscopy for people at risk of familial adenomatous polyposis, and colonoscopy for people at risk of hereditary nonpolyposis colon cancer.
CRD commentary
The research question in this review was very broad. The review included both people at normal risk and those at higher risk of CRC. It also included numerous screening strategies and multiphase as well as single-phase techniques. This broad scope means that the findings are complex. Only one database was searched and non-English language studies were excluded. Thus, it is possible that not all relevant studies were included.
It was difficult to assess the quality of the findings because the procedures used to select the studies, assess validity and extract the data were not described in full. Although a checklist for assessing validity was used, it was unclear how different levels of evidence were weighted when drawing the conclusions. The authors did not discuss possible sources of bias. It was unclear how many participants were involved in some cohort or case-control studies.
The synthesis of the findings was somewhat difficult to follow. The narrative summary was not organised according to study quality, e.g. the evidence from randomised trials was sometimes presented following the results of case-control or cohort studies. Different data were provided for different studies. In some cases odds ratios or compliance estimates were presented; in other instances, specificity and relative risks were described, making comparisons difficult. The authors did not attempt to pool estimates of relative risk or to weight the data in any way. The authors reported ranges in sensitivity, but specificity estimates were not reported alongside. Since sensitivity and specificity are highly related, it may be important to report them together for each study where possible.
Overall, although this review provided much detail about studies of different screening methods, it was difficult to assess whether the final conclusions are valid due to inconsistent data presentation and incomplete methodological details.
Implications of the review for practice and research
Practice: The authors suggested that annual or biennial FOBT and flexible sigmoidoscopy may be beneficial in asymptomatic people aged over 50 years who are at normal risk of CRC. The relative benefits of FOBT, sigmoidoscopy and initial screening with colonoscopy are uncertain in this population. For people with an above average risk of CRC, there is some evidence supporting genetic testing, flexible sigmoidoscopy for people at risk of familial adenomatous polyposis, and colonoscopy for people at risk of hereditary nonpolyposis colon cancer.
Research: The authors suggested that there is a need for better risk stratification in screening. There is also a need for randomised trials on the effectiveness and feasibility of screening methods not covered by this review.
